Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Dr. Mahendrabhai Munjapara inaugurated the AYUSH eMela, Virtual Conference organized by PHDCCI

    PHD Chamber in collaboration with Ministry of AYUSH, Govt. of India is organizing AYUSH E-Mela Virtual Conference cum Expo 2021 from 24th-26th February 2022.

  • PCI mandate exit exam after diploma in pharmacy

    Pharmacy Council of India has mandated exit exam for D.Pharm candidates to register as pharmacist under section 12 of the Pharmacy Act, 1948. No person shall be registered as a Diploma in Pharmacy Exit Examination candidate unless he has passed Diploma in Pharmacy course from an institution approved by the PCI.

  • Indian made medicinal products illegally imported in Switzerland

    A large number of Indian made medicinal products illegally imported in Switzerland were seized by Swissmedic and the Federal Office for Customs and Border Security. These contained COVID-19 medicines like ivermectin, hydroxychloroquine or antibiotics and erectile stimulants from India.

    Swiss government agency along with customs had secured 9,421 packages containing illegally imported medicinal products during 2021. This is a significant increase on the previous year, when there were 6,733 such packages.

  • TRIPS waiver must be agreed for COVID-19, says MSF

    Medecins Sans Frontieres, International medical charity called on the European Union, the UK and Switzerland to swiftly adopt the landmark Waiver, which would lift intellectual property monopolies on COVID-19 medical tools, and is currently supported by more than 100 low and middle income countries. MSF also urged the US to show concrete leadership to accelerate the negotiations and to broaden the scope of its support beyond only vaccines to include medicines and diagnostics.

  • Experimental combinatorial therapy eliminates an incurable brain tumour

    A study recently accepted for publication in The Journal of Clinical Investigation describes a new and effective therapy to treat glioblastoma: the concomitant use of ADI-PEG20 together with focal brain radiotherapy. This double treatment completely eliminated the tumour in the animal models used in the study. This study was carried out by researchers from the Institute of Biomedicine of Seville: Dr. Manuel Sarmiento Soto, Dr. Juan García Revilla, and Dr. José Luis Venero, in collaboration with Dr. Nabil Hajji and Dr. Nel Syed of Imperial College London.

  • Development of nanoengineered bacteria for cancer optotheranostics

    There is substantial interest regarding the understanding and designing of nanoengineered bacteria to combat various fatal cancerous diseases. However, conventional nanotechnological approaches adopt genetic manipulation for attenuating and improving the efficacy of bacteria. In addition, complicated chemical reactions were essential in the previous approaches.

  • Taro to acquire Alchemee From Galderma

    Galderma and Taro Pharmaceutical Industries Ltd announced they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma. The agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv® brand.

  • Binnopharm to acquire two anti bacterial brands from Dr. Reddys in the Russia

    The Sistema Group company Binnopharm Group, one of the leading pharmaceutical production companies in Russia via its affiliate Joint Stock Company Alium, and Dr. Reddys Laboratories Ltd an integrated global pharmaceutical company, today announced the signing of a deal that will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet and Levolet brands from Dr. Reddys in Russia, Uzbekistan and Belarus. The portfolio includes various dosage forms such as tablets, solution for infusions and eye drops.

  • Strides receives USFDA approval for Amantadine Hydrochloride Softgel Capsules

    Strides Pharma Science Limited announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Amantadine Hydrochloride Softgel Capsules USP, 100 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Symmetrel Capsules, 100 mg, of Endo Pharmaceuticals, Inc (Endo).

  • NIAB discover potential biomarker for Japanese encephalitis virus

    NIAB discover potential biomarker, NS 1 protein for Japanese encephalitis virus. Non-Structural 1 protein, a potential diagnostic biomarker for Japanese encephalitis virus. A diagnostic biomarker refers to a biological parameter that aids the diagnosis of a disease and may serve in determining disease progression or success of treatment.

Subscribe to Pharma News